版本:
中国

BRIEF-Prometic presents new data on PBI-4050 and plasminogen

May 23 Prometic Life Sciences Inc:

* Prometic presents new data on PBI-4050 and plasminogen at American Thoracic Society's 2017 international conference

* Prometic Life Sciences Inc - PBI-4050 + nintedanib provided a statistically significant benefit over pbi-4050 + pirfenidone

* Prometic Life Sciences - intends to initiate a second phase 2/3 placebo-controlled trial in which IPF patients who failed to tolerate either nintedanib or pirfenidone

* Prometic Life Sciences Inc - Prometic plans to initiate both studies in second half of 2017. Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐